Pavletić Z, Labar B
Klinika za unutarnje bolesti KBC Rebro, Medicinski fakultet Sveucilista Zagrebu.
Lijec Vjesn. 1990 Sep-Oct;112(9-10):339-46.
Hematopoietic growth factors are glycoproteins that stimulate the proliferation and differentiation of hematopoietic progenitor cells. Due to several technical advances, first of all to the techniques of recombinant DNA, it has become possible today to produce them highly-purified and in amounts big enough to enable its application in clinical trials. Until now, 5 hematopoietic growth factors have been studied on humans. In early clinical trials their safety and favourable biological efficacy has been proved. Obvious effectivity in vivo significantly broadens frontiers of possible therapeutic effects in several clinical conditions that include primary or secondary insufficiency of hematopoiesis. Their future applications have to include combinations of several different hematopoietic growth factors or their combinations with cytostatic drugs or immunomodulators.
造血生长因子是刺激造血祖细胞增殖和分化的糖蛋白。由于多项技术进步，首先是重组DNA技术，如今已能够高度纯化地生产这些因子，并且产量足以使其应用于临床试验。到目前为止，已经在人体上研究了5种造血生长因子。在早期临床试验中，已证明了它们的安全性和良好的生物学疗效。其在体内的显著有效性显著拓宽了在包括原发性或继发性造血功能不全在内的多种临床病症中可能的治疗效果的范围。它们未来的应用必须包括几种不同造血生长因子的联合使用，或者它们与细胞抑制药物或免疫调节剂的联合使用。
